Walliser Ulrich, Fenner Albrecht, Mohren Nicole, Keefe Thomas, deVries Frerich, Rundfeldt Chris
Clinic for Horses Kirchheim, Nuertingerstrasse 200, 73230, Kirchheim, Germany.
Boehringer Ingelheim Vetmedica GmbH, 55216, Ingelheim am Rhein, Germany.
BMC Vet Res. 2015 May 15;11:113. doi: 10.1186/s12917-015-0427-4.
The benefit of pre and post-operative administration of non-steroidal anti-inflammatory drugs for the relief of post-operative pain and control of inflammation in horses following orthopaedic surgery has not been previously investigated in controlled clinical field trials, and the utility of such treatment is a matter of ongoing dispute. Recently the utility of post-operative pain management was emphasized. It was therefore our aim to determine the efficacy of meloxicam in horses following partial resection of fractured splint bones. This condition was selected since the limited extent of the insult and the defined surgical intervention allowed the conduct of a randomized, double blinded, placebo-controlled, parallel group, multi-centre clinical field study in a homogenous patient population.
Sixty-six client owned horses requiring unilateral partial splint bone resection were recruited in 15 centres in Germany and were allocated in a 1:1 ratio to receive meloxicam, 0.6 mg/kg for 5 days. Lameness at trot grades prior to surgery were similar in the meloxicam and placebo treatment groups but were significantly lower in the meloxicam group on day 6 post surgery. Clinical scores for soft tissue swelling and assessment of analgesic and anti-inflammatory efficacy by the investigators at the end of the study were significantly better for the meloxicam compared to the placebo group. No treatment-related adverse reactions were observed.
The administration of meloxicam i.v. once prior to surgery followed by once daily oral administration for four consecutive days is efficacious for the control of post-operative pain and inflammation in horses undergoing orthopaedic surgery.
非甾体类抗炎药术前和术后给药对缓解马匹骨科手术后的疼痛及控制炎症的益处,此前尚未在对照临床现场试验中进行研究,且这种治疗方法的效用仍存在争议。最近,术后疼痛管理的效用得到了强调。因此,我们的目的是确定美洛昔康对马匹骨折掌骨部分切除术后的疗效。选择这种情况是因为损伤程度有限且手术干预明确,从而能够在同质患者群体中进行一项随机、双盲、安慰剂对照、平行组、多中心临床现场研究。
在德国的15个中心招募了66匹需要单侧掌骨部分切除的客户拥有的马匹,并按1:1的比例分配,接受美洛昔康治疗,剂量为0.6mg/kg,持续5天。术前小跑时的跛行等级在美洛昔康组和安慰剂组中相似,但在术后第6天,美洛昔康组明显更低。在研究结束时,与安慰剂组相比,美洛昔康组的软组织肿胀临床评分以及研究者对镇痛和抗炎疗效的评估明显更好。未观察到与治疗相关的不良反应。
术前静脉注射一次美洛昔康,随后连续四天每日口服一次,对接受骨科手术的马匹控制术后疼痛和炎症有效。